Baxter International (BAX)
NYSEHealth CareMedical - Instruments & SuppliesSnapshot 2026-11-04
$26.50+3.96%
Close 2026-11-04 · 1-day change
NYSEHealth CareMedical - Instruments & SuppliesSnapshot 2026-11-04
Research Workspace
Put BAX beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Health Care Equipment: fringe margins under pressure (4q confirmed)
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Adjusted EPS near $1.95 in 2026: Direct metric needs a verified mapping.
View ThesisRevenue is growing steadily — about 5% over the past year.
View GrowthMiddle-of-the-pack quality for its industry.
View QualityManagement screens strong on capital allocation, margins, the balance sheet, market reaction to earnings.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationModerate volatility — typically moves about 2% a day.
View RiskBaxter's 2026 outlook rests on 3% to 4% organic sales growth. Revenue grew 5% year over year in the last two quarters. The company beat Q3 estimates by 13.7%. It trades at 13x earnings versus a 30x peer median. Expectations look modest compared to our internal view. The primary pillar is under pressure. The thesis comparison is not yet verified. Peer multiples imply a price about 14% above where it trades. The thesis is on watch. This read is provisional.
Trailing returns as of 2026-11-04. BAX is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 15 analysts currently covering BAX (as of Nov 2026).
Based on 5 Wall Street analysts offering 12-month price targets for BAX in the last 4 months.
Continue this research
Compare BAX with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| BAX Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 14 valuation methods, at three horizons. As of 2026-11-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Health Care Equipment — fair value, gap to price, and forward P/E.
Compare the value case
Put BAX next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Reiterate and raise full-year 2026 financial outlook
Q3 earnings call provides a direct update on 2026 outlook and management priorities.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-11-04. EPS is implied from price ÷ P/E. Not investment advice.
Current $26.50
The last 12 months of price, then the range of analyst 12-month targets from today’s $26.50.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Below average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Advances: Reiterate and raise full-year 2026 financial outlook
Projects 2026 sales growth and EPS targets, reaffirming the tracked outlook objective.
Advances: Reiterate and raise full-year 2026 financial outlook
Reported Q3 earnings beat supports the outlook objective, though the share decline tempers the signal.
FDA warning-letter risk at a Baxter facility may disrupt operations and create regulatory remediation costs.
Margin recovery complications could hinder financial outlook.
Advances: Reiterate and raise full-year 2026 financial outlook
Strong Q2 growth supports raised full-year 2026 outlook.
Advances: CFO transition and leadership changes
CFO transition aligns with leadership objectives and may enhance performance.
Threatens: CFO transition and leadership changes
CFO transition may disrupt financial outlook and strategy execution.
